| Institution | PI Name | Title |
|---|
| Alphavax Human Vaccines, Inc. | Jeffrey Chulay | Alphavirus Replicon Vaccines against Influenza |
| Alphavax Human Vaccines, Inc. | Kurt Kamrud | Development of an Alphavirus Replicon Vaccine against Smallpox |
| Avecia, Ltd. | Allan Watkinson | Delivering Improved Anthrax vaccine stability |
| Chesapeake Perl | Richard Welch | Smallpox subunit vaccine in the C-PERL expression system |
| Corixa Corporation | Witold Cieplak | Rapid Acting Vaccine for Pandemic Influenza |
| Elusys Therapeutics | Linda Nardone | Formulation Development for an Intramuscular Administration against Anthrax |
| Hebrew University of Jerusalem | Raymond Kaempfer | Broad-Spectrum Antagonist of Superantigen Toxins |
| Infectious Disease Research Institute | Steven Reed | Development & Manufacture of an MDR Tuberculosis Vaccine |
| Iquum, Inc. | Bertrand Lemieux | Closed-Tube Nucleic Acid Diagnostic system |
| Isis Pharmaceuticals | Lawrence Blyn | Multivariate pathogen diagnostic products |
| Ligocyte Pharmaceuticals, Inc. | Susan Wimer-Mackin | Preclinical Development of a Non-Invasive Anthrax Vaccine |
| Meso Scale Diagnostics, LLC | George Sigal | Multiplexed POC Diagnostic System for Bio-Threat Agents |
| Tulane University of Louisiana | Robert Garry | Recombinant antigen multiagent diagnostic assays |
| Vaxin, Inc. | De-Chu Tang | Adenovirus-vectored nasal anthrax vaccine |
| Vaxin, Inc. | Dennis Trent | Replication-Defective Adenovirus-Vectored Pandemic Influenza |
| Vical, Inc. | Larry Smith | Biodefense vaccine for pandemic influenza |